Selected stock price target news of the day - March 10th, 2025

By: Matthew Otto

UNITY Biotechnology Reports Financial Results and Clinical Progress for Q4 and Full Year 2024

UNITY Biotechnology reported its financial results, while highlighting upcoming clinical milestones for UBX1325 (foselutoclax), its investigational treatment for diabetic macular edema (DME). DME is a leading cause of vision loss in people with diabetes, affecting approximately 21 million individuals worldwide, with nearly one million cases in the United States alone.

As of December 31, 2024, UNITY had $23.2 million in cash, cash equivalents, and marketable securities, down from $43.2 million at the end of 2023. Net loss for 2024 was $26.0 million, improving from a $39.9 million loss in 2023. Cash used in operations decreasing to $20.9 million from $37.1 million.

Fourth-quarter results showed an $8.4 million net loss, up from $4.3 million in the prior-year quarter. Cash used in operations at $5.9 million compared to $6.7 million. Research and development expenses declined to $13.0 million for the full year. General and administrative expenses also decreased to $15.5 million from $19.0 million.

Analysts Reaffirm Buy Ratings and Price Targets

Chardan Capital analyst Daniil Gataulin maintained a Buy rating and a $6 price target.
HC Wainwright & Co. analyst Matthew Caufield Kept a Buy rating and a $8 price target.

Which Analyst has the best track record to show on UBX?

Analyst Andreas Argyrides (WEDBUSH) currently has the highest performing score on UBX with 3/5 (60%) price target fulfillment ratio. His price targets carry an average of $-1.11 (-35.69%) potential downside. UNITY Biotechnology stock price reaches these price targets on average within 66 days.

Bally’s Reports Q4 and Full-Year 2024 Results; Proposes Investment in Star Entertainment

Bally’s Corporation reported fourth-quarter 2024 revenue of $580.4 million, a 5.1% decline from $611.7 million in Q4 2023. Full-year 2024 revenue reached $2.45 billion, slightly higher than the $2.45 billion reported in 2023.

The Casinos & Resorts segment generated $324.4 million in Q4 revenue, down 5.2% from $342.3 million in the prior year. International Interactive revenue declined 9.1% to $214.5 million, with U.K. operations growing 11.3%, while North America Interactive revenue increased 24.4% to $41.5 million.

Bally’s reported an adjusted EBITDAR decline of 14.6% in its Casinos & Resorts segment to $80.9 million, citing higher costs and lower revenue flow-through. Also completed transactions with Standard General and The Queen Casino & Entertainment, with Queen’s four properties contributing $57.6 million in Q4 revenue and $225.2 million for the full year.

Bally’s submitted a $158 million offer to acquire just over 50% of Star Entertainment, an Australian casino operator facing financial distress. Star reported available cash of $48.8 million at the end of December 2024 and has accumulated regulatory fines exceeding $72 million since 2022. Star’s debt restructuring efforts include a $588.6 million refinancing proposal with a $156.5 million bridging facility and a separate $407 million debt refinancing proposal from Oaktree. Star is also selling a 50% stake in its Queen’s Wharf project in Brisbane to Far East Consortium International and Chow Tai Fook Enterprises.

Analyst Lowers Price Target Amid Revenue Decline and Investments

Barclays analyst Brandt Montour maintained an Equal-Weight rating and lowered the price target from $18 to $14.

Which Analyst has the best track record to show on BALY?

Analyst Jeffrey Stantial (STIFEL) currently has the highest performing score on BALY with 4/7 (57.14%) price target fulfillment ratio. His price targets carry an average of $1.01 (7.78%) potential upside. Bally’s Corporation stock price reaches these price targets on average within 32 days.

GMS Reports Fiscal Q3 2025 Results: Pricing Resilience Amid Demand Challenges

GMS reported fiscal third-quarter 2025 results, with net sales reaching $1.3 billion, a 0.2% increase, slightly below the consensus estimate of $1.31 billion. Organic net sales declined 6.7%.

GMS posted a net loss of $21.4 million, or $0.55 per diluted share, primarily due to a $42.5 million non-cash goodwill impairment charge. Adjusted net income fell to $36.2 million, or $0.92 per diluted share, from $68.8 million, or $1.70 per diluted share, a year ago. Adjusted EBITDA decreased 27.3% to $93.0 million, with an EBITDA margin of 7.4%, down from 10.2% in the prior-year quarter. Steel Framing sales saw the largest decline, falling 11.6% to $179.7 million, while Ceilings sales increased 16.0% to $180.7 million. Gross margin contracted by 180 basis points to 31.2%, driven by weak demand, lower vendor incentives, and pricing pressures, particularly in Steel. However, GMS reported Q3 EPS of $1.70, beating the analyst estimate of $1.61 by $0.09.

GMS generated $94.1 million in cash from operating activities and $83.1 million in free cash flow. Net debt leverage increased to 2.4 times, compared to 1.5 times a year ago, with total debt standing at $1.4 billion. SG&A expenses rose to $310.8 million, representing 24.7% of net sales, up from 23.5% in the prior-year quarter, with cost increases partly offset by a $20 million annualized cost reduction initiative. GMS repurchased 445,163 shares for $39.3 million, leaving $218.4 million in remaining share repurchase authorization.

Analysts Adjust Price Targets Amid Market Challenges

Barclays analyst Matthew Bouley maintained an Equal-Weight rating, yet lowered the price target from $80 to $71.
Loop Capital analyst Jeffrey Stevenson cut the price target to $80.

Which Analyst has the best track record to show on GMS?

Analyst Kurt Yinger (D.A. DAVIDSON) currently has the highest performing score on GMS with 4/4 (100%) price target fulfillment ratio. His price targets carry an average of $-3.05 (-3.14%) potential downside. GMS Systems stock price reaches these price targets on average within 68 days.